The Clinical Impact of Camera-Based Positron Emission Tomography Imaging in Patients With Recurrent Colorectal Cancer
Authors:
- Hedva LermanHLHedva Lerman
- Mordechai GutmanMGMordechai Gutman
- Arie FigerAFArie Figer
- Genady LivshitzGLGenady Livshitz
- Einat Even-SapirEEEinat Even-Sapir
- 1 January 2004
- journal article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 39 (1) , 8-12
Abstract
F18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) studies have clinical value in suspected recurrent or metastatic colorectal cancer cases. Because this modality is not accessible for many patients, a camera-based FDG (CB-FDG) coincidence imaging was suggested as an alternative. Although inferior in resolution to a dedicated PET system, it can make FDG studies available to more patients. We assessed the clinical value of CB-FDG in patients with recurrent colorectal cancer. The disease stage and treatment approach in 83 patients were twice determined by an oncologist and a surgeon, first based on the patient's records and blind to CB-FDG findings and then with the inclusion of FDG results in the decision-making analysis. On a lesion-based analysis, the sensitivity of CB-FDG was 95% and the specificity was 81% compared with 88% and 64%, respectively, for computed tomography. Adding FDG findings led to disease-stage alteration in 47 patients (57%), upstaging in 35 (42%), and downstaging in 12 (15%). FDG localized the tumor sites in 21 of 26 patients (81%) with suspected clinical recurrence and a negative conventional imaging workup. In 8 patients, FDG ruled out viable tumor tissue suggested by other modalities. The oncologist's suggested treatment approach was altered in 54% of the patients and the surgeon altered the decision on operability in 28%. CB-FDG assessment has clinical value for both staging and selecting treatment in patients with recurrent colorectal cancer and can be considered an alternative to an nonaccessible dedicated PET system.Keywords
This publication has 12 references indexed in Scilit:
- FDG-PET improves the staging and selection of patients with recurrent colorectal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective StudyJournal of Clinical Oncology, 2002
- Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective StudyJournal of Clinical Oncology, 2002
- The Role of Fluorine-18-fluorodeoxyglucose (FDG) Dual-head Gamma Camera Coincidence Imaging in Patients with Colorectal Cancer and Unexplained Rising Levels of Carcinoembryonic Antigen (CEA)Gastrointestinal Oncology, 2002
- The clinical value of 18F-FDG detection with a dual-head coincidence camera: a reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectumDiseases of the Colon & Rectum, 2000
- Whole-Body PET Imaging With [18F]Fluorodeoxyglucose in Management of Recurrent Colorectal CancerArchives of Surgery, 1999
- Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignanciesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.Radiology, 1998
- Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.Radiology, 1998